Bupropion for the treatment of apathy in Huntington’s disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial

• Harald Gelderblom,

  Current address: Department of Medicine, National Association of Statutory Health Insurance Funds, Berlin, Germany

  Affiliation Department of Neuropsychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany

  ⨯
• Torsten Wüstenberg,

  Affiliation Department of Psychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany

  ⨯
• Tim McLean,

  Affiliation European Huntington’s Disease Network, Ulm, Germany

  ⨯
• Lisanne Mütze,

  Affiliation European Huntington’s Disease Network, Ulm, Germany

  ⨯
• Wilhelm Fischer,

  Affiliation Department of Neurology, University of Ulm, Ulm, Germany

  ⨯
• Carsten Saft,

  Affiliation Department of Neurology, Huntington-Center NRW, St. Josef Hospital, Ruhr-University, Bochum, Germany

  ⨯
• Rainer Hoffmann,

  Affiliation Department of Neurology, Huntington-Center NRW, St. Josef Hospital, Ruhr-University, Bochum, Germany

  ⨯
• Sigurd Süssmuth,

  Affiliation European Huntington’s Disease Network, Ulm, Germany

  ⨯
• Peter Schlattmann,

  Affiliation Institute of Medical Statistics, Computer Sciences and Documentation, Jena Universityhospital, Jena, Germany

  ⨯
• Erik van Duijn,

  Affiliation Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands

  ⨯
• Bernhard Landwehrmeyer,

  Affiliations European Huntington’s Disease Network, Ulm, Germany, Department of Neurology, University of Ulm, Ulm, Germany

  ⨯
• Josef Priller

  * E-mail: Josef.priller@charite.de

  Affiliations Department of Neuropsychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany, Cluster of Excellence NeuroCure, DZNE and BIH, Berlin, Germany

  ⨯